Stefan Duensing

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 4

Top Topics

Regulatory T Cells

Prostate Cancer

Top Venues

Cancer immunology, immunotherapy : CII

JMIR medical informatics

Genes, chromosomes & cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Magdalena Goertz, Michael Byczkowski, Mathias Rath, Viktoria Schütz, Philipp Reimold, Claudia Gasch, Tobias Simpfendörfer, Keno März, Alexander Seitel, Marco Nolden, Tobias Roß, Diana Mindroc-Filimon, Dominik Michael, Jasmin Metzger, Sinan Onogur, Stefanie Speidel, Lars Mündermann, Johannes Fallert, Michael Müller, Magnus von Knebel-Doeberitz, Dogu Teber, Peter Seitz, Lena Maier-Hein, Stefan Duensing, Markus Hohenfellner
A Platform and Multisided Market for Translational, Software-Defined Medical Procedures in the Operating Room (OP 4.1): Proof-of-Concept Study. JMIR medical informatics 10 (1) (2022)
Cathleen Nientiedt, Anette U Duensing, Stefanie Zschäbitz, Dirk Jäger, Markus Hohenfellner, Albrecht Stenzinger, Stefan Duensing
PARP inhibition in prostate cancer. Genes, chromosomes & cancer 60 (5) (2020)
Maximilian Jenzer, Peter Keß, Cathleen Nientiedt, Volker Endris, Maximilian Kippenberger, Jonas Leichsenring, Fabian Stögbauer, Josh Haimes, Skyler Mishkin, Brian Kudlow, Adam Kaczorowski, Stefanie Zschäbitz, Anna-Lena Volckmar, Holger Sültmann, Dirk Jäger, Anette Duensing, Peter Schirmacher, Markus Hohenfellner, Carsten Grüllich, Albrecht Stenzinger, Stefan Duensing
The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer immunology, immunotherapy : CII 68 (10) (2019)
María Ángeles Tapia-Laliena, Nina Korzeniewski, Samuel Peña-Llopis, Claudia Scholl, Stefan Fröhling, Markus Hohenfellner, Anette Duensing, Stefan Duensing
Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability. Oncogenesis 8 (1) (2019)